Cyclosporine Plus Methotrexate or Alemtuzumab

Inclusion criteria: 1. Having an identical Human Leukocyte Antigens (HLA) or a mismatched family donor. 2. Age between 45 and 65 years (outside this age range at the discretion of each center). 3. Indications: * Follicular lymphoma with one of the following characteristics: 1. Poor prognosis follicular NHL (3 or more factors by Federico et al: erythrocyte sedimentation rate (ESR)\> 30, male,\> 60 years, high LDH\> 2 extranodal areas, pathologic stage (PS) \>2 or The International Prognostic Index (IPI) 3 or high lactate dehydrogenase (LDH) or micro Beta 2) failing to achieve CR with regimens including fludarabine and anti CD20 (cluster of differentiation antigen 20 ). 2. 2nd CR (complete response) or PR (partial response) not candidates for autologous transplantation; 3. persistent disease or relapse after autologous transplantation. * Other low-grade lymphomas: 1. relapsed after autologous transplantation. 2. autologous transplant candidates which can not be performed because of the inability to collect a sufficient number of cells, steam cells disease persistence, etc.. * Chronic lymphocytic leukemia with one of the following characteristics: 1. "B" symptoms: weight loss \>10% in the last 6 months, fever \>38ºC (degrees centigrade) for 14 days without infection, night sweats without infection 2. lymphadenopathy \>10 cm or progressive, progressive splenomegaly 3. Anemia and/or thrombocytopenia secondary to bone marrow infiltration 4. Diffuse lymphocytic infiltration of the bone marrow 5. Progressive lymphocytosis (\>50% in 2 months) or a lymphocyte doubling time \<12 months Any of the above criteria is an inclusion criteria in the protocol in patients who have received at least one line of treatment including fludarabine 6. Patients with poor prognostic cytogenetic abnormalities: 17p-, 11q-with VDJ unmutated 4. Patients must also meet the following general requirements: 1. Performance status \<3 (Zubrod score, Eastern Cooperative Oncology Group (ECOG) performance status or WHO (World Health Organization) ) 2. forced expiratory volume at one second (FEV1) \> 39%, lung diffusing capacity for carbon monoxide (DLCO) and forced vital capacity (FVC) \> 39% of the theoretical values 3. Total bilirubin and transaminases \<3 x the normal maximum value, unless attributable to base haemopathy 4. Creatinine \<2 x normal maximum and clearance\> 40 mL / min unless attributable to his base haemopathy 5. No evidence of symptomatic disease, cirrhosis or active hepatitis 6. Negative serology for HIV 7. Written informed consent Exclusion criteria: 1. Impaired hepatic or renal function superior to that described above 2. Presence of serious diseases that prevent chemotherapy treatments 3. Presence of psychiatric comorbidity 4. HIV infection 5. Other prior neoplasm 6. Do not have signed informed consent 7. Pregnant or at risk of pregnancy by inadequate contraceptive measures. 8. Patients diagnosed with chronic lymphocytic leukemia (CLL) transformation to more aggressive cytologic or histologic forms (prolymphocytic leukemia, large cell lymphoma, Hodgkin's disease) and those affected with autoimmune hemolytic anemia